Part 3.15 / M35 (Part 6/6)

Index-Nr.

►M18  Chemische Bezeichnung ◄

EG-Nr.

CAS-Nr.

Einstufung

Kennzeichnung

►M18  Spezifische Konzentrationsgrenzen, M-Faktoren und ATE (*1)  ◄

Anmerkungen

►M16   ►C14  Kodierung der Gefahrenklassen und -kategorien ◄  ◄

Kodierung der Gefahrenhinweise

Piktogramm, Kodierung der Signalworte

Kodierung der Gefahrenhinweise

Kodierung der ergänzenden Gefahrenmerkmale

▼M16

607-034-00-0

Methylacrylat;

Methlproenoat

202-500-6

96-33-3

Flam. Liq. 2

Acute Tox. 3

Acute Tox. 4

Acute Tox. 4

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

H225

H331

H312

H302

H335

H315

H319

H317

GHS02

GHS06

Dgr

H225

H331

H312

H302

H335

H315

H319

H317

Inhalation: ATE = 3 mg/L (Dämpfe)

dermal: ATE = 1 100  mg/kg KG

Oral: ATE = 500 mg/kg KG

D

607-223-00-8

Transfluthrin (ISO); 2,3,5,6-Tetrafluorbenzyl (1R,3S)-3-(2,2-dichlorvinyl)-2,2-dimethylcyclopropancarboxylat

405-060-5

118712-89-3

Carc. 2

Acute Tox. 4

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H370 (Nervensystem)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H370 (Nervensystem)

H410

EUH066

Oral: ATE = 580 mg/kg KG

M = 1 000

M = 1 000

607-246-00-3

Allylmethacrylat;

2-Methyl-2-propensäure 2-propenylester

202-473-0

96-05-9

Flam. Liq. 3

Acute Tox. 2

Acute Tox. 3

Acute Tox. 4

Aquatic Acute 1

H226

H330

H311

H302

H400

GHS02

GHS06

GHS09

Dgr

H226

H330

H311

H302

H400

Inhalation: ATE = 1,5 mg/L (Dämpfe)

dermal: ATE = 300 mg/kg KG

Oral: ATE = 400 mg/kg KG

607-766-00-0

Tetramethylendimethacrylat

218-218-1

2082-81-7

Skin Sens. 1B

H317

GHS07

Wng

H317

607-767-00-6

7,7,9(oder 7,9,9)-Trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecan-1,16-diyl bismethacrylat

276-957-5

72869-86-4

Skin Sens. 1B

H317

GHS07

Wng

H317

607-768-00-1

2,2’-Ethylendioxydiethyldimethacrylat

203-652-6

109-16-0

Skin Sens. 1B

H317

GHS07

Wng

H317

607-769-00-7

Bifenox (ISO); Methyl-5-(2,4-dichlorphenoxy)-2-nitrobenzoat

255-894-7

42576-02-3

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

Oral:

ATE = 1 500  mg/kg KG

M = 1 000

M = 1 000

612-004-00-5

Triethylamin

204-469-4

121-44-8

Flam. Liq. 2

Acute Tox. 3

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1A

Eye Dam. 1

H225

H331

H311

H301

H314

H318

GHS02

GHS06

GHS05

Dgr

H225

H331

H311

H301

H314

Inhalation: ATE = 7,2 mg/L (Dämpfe)

dermal: ATE = 300 mg/kg KG

oral: ATE = 100 mg/kg KG STOT SE 3; H335: C ≥ 1 %

612-049-00-0

Di-n-Butylamin

203-921-8

111-92-2

Flam. Liq. 3

Acute Tox. 2

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1B

Eye Dam. 1

H226

H330

H311

H301

H314

H318

GHS02

GHS06

GHS05

Dgr

H226

H330

H311

H301

H314

EUH 071

Inhalation: ATE = 1,2 mg/L (Dämpfe) dermal: ATE = 300 mg/kg KG

Oral: ATE = 220 mg/kg KG

612-056-00-9

N,N-Dimethyl-m-toluidin; [1]

N,N-Dimethyl-o-toluidin [2]

204-495-6 [1] 210-199-8 [2]

121-72-2 [1] 609-72-3 [2]

Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3

H331

H311

H301

H373 **

H412

GHS06 GHS08

Dgr

H331

H311

H301

H373 **

H412

*

C

612-295-00-9

Benfluralin (ISO); N-Butyl-N-ethyl-α,α-trifluor-2,6-dinitro-p-toluidin;

217-465-2

1861-40-1

Carc. 2

Repr. 2

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H315

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H315

H319

H317

H410

M = 10

M = 10

612-296-00-4

N,N-Dimethyl-p-toluidin

202-805-4

99-97-8

Carc. 1B

Acute Tox. 4

Acute Tox. 3

STOT RE 2

Aquatic Chronic 3

H350

H332

H301

H373 (Blutkreislauf, Atemwege)

H412

GHS08

GHS06

Dgr

H350

H332

H301

H373 (Blutkreislauf, Atemwege)

H412

Inhalation:

ATE = 1,4 mg/L (Stäube oder Nebel)

Oral:

ATE = 140 mg/kg KG

612-297-00-X

1-Phenylethan-1-on (1-Phenylethyliden)hydrazon

211-979-0

729-43-1

Skin Sens. 1

H317

GHS07

Wng

H317

612-298-00-5

1,4-Benzoldiamin, N,N’-gemischte Ph und Tolylderivate

273-227-8

68953-84-4

Repr. 1B

Skin Sens. 1

H360FD

H317

GHS08

GHS07

Dgr

H360FD

H317

613-088-00-6

1,2-Benzisothiazol-3(2H)-on; 1,2-Benzisothiazolin-3-on

220-120-9

2634-33-5

Acute Tox. 2

Acute Tox. 4

Skin Irrit. 2

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H315

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H315

H318

H317

H410

Inhalation:

ATE = 0,21 mg/L (Stäube oder Nebel)

Oral: ATE = 450 mg/kg KG

Skin Sens. 1A; H317: C ≥ 0,036 %

M = 1

M = 1

613-127-00-7

Mepiquatchlorid (ISO); 1,1-Dimethylpiperidiniumchlorid

246-147-6

24307-26-4

Acute Tox. 4

Acute Tox. 3

Aquatic Chronic 3

H332

H301

H412

GHS06

Dgr

H332

H301

H412

Inhalation: ATE = 2,8 mg/L (Stäube oder Nebel)

Oral:

ATE = 270 mg/kg KG

613-307-00-5

Clothianidin (ISO); (E)-1-(2-Chlor-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidin

433-460-1

210880-92-5

Repr. 2

Acute Tox. 4

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H361f

H302

H370 (Nervensystem)

H400

H410

GHS08

GHS07

GHS09

Dgr

H361f

H302

H370 (Nervensystem)

H410

Oral: ATE = 390 mg/kg KG

M = 10

M = 100

613-346-00-8

4-Nitrosomorpholin

—

59-89-2

Carc. 1B

Muta. 2

STOT RE 1

H350

H341

H372 (Leber)

GHS08

Dgr

H350

H341

H372 (Leber)

Carc. 1B; H350: C ≥ 0,001 %

613-347-00-3

Difenoconazol (ISO); 1-({2-[2-Chlor-4-(4-chlorphenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazol; 3-Chlor-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenylether

—

119446-68-3

Carc. 2

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H319

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H319

H410

Oral:

ATE = 1 450  mg/kg KG

M = 10

M = 10

613-348-00-9

9-[2-(Ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthyliumchlorid; Basic Red 1

213-584-9

989-38-8

Acute Tox. 3

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H301

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H301

H318

H317

H410

Oral:

ATE = 280 mg/kg KG

M = 10

M = 1

613-349-00-4

4-Methylimidazol

212-497-3

822-36-6

Carc. 1B

Repr. 1B

H350

H360Fd

GHS08

Dgr

H350

H360Fd

615-051-00-X

3,3’-Dimethylbiphenyl-4,4’-diyldiisocyanat

202-112-7

91-97-4

Carc. 2

Resp. Sens. 1

Skin Sens. 1A

H351

H334

H317

GHS08

Dgr

H351

H334

H317

Skin Sens. 1A; H317: C ≥ 0,001 %

616-035-00-5

Cymoxanil (ISO); 2-Cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamid; [1]

(2E)-2-Cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamid; [2]

261-043-0 [1]

- [2]

57966-95-7 [1]

166900-80-7 [2]

Repr. 2

Acute Tox. 4

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H302

H373 (Blutkreislauf, Thymusdrüse, Augen)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361fd

H302

H373 (Blutkreislauf, Thymusdrüse, Augen)

H317

H410

Oral: ATE = 360 mg/kg KG

M = 1

M = 1

616-104-00-X

Benalaxyl (ISO); Methyl-N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninat.

275-728-7

71626-11-4

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

Oral: ATE = 1 000  mg/kg KG

M = 1

M = 1

616-241-00-5

Foramsulfuron (ISO); 2-{[(4,6-Dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl-4-formamido-N,N-dimethylbenzamid; 1-(4,6-Dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)harnstoff

—

173159-57-4

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1 000

M = 100

616-242-00-0

Picolinafen (ISO); N-(4-Fluorphenyl)-6-[3-(trifluormethyl)phenoxy]-2-pyridincarboxamid; 4′-Fluor-6-[(α,α,α-Trifluor-m-tolyl)oxy]picolinanilid

—

137641-05-5

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H373 (Blutkreislauf, Schilddrüse)

H400

H410

GHS08

GHS09

Wng

H373 (Blutkreislauf, Schilddrüse)

H410

M = 1 000

M = 1 000